Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 1;2015(7):CD009864.
doi: 10.1002/14651858.CD009864.pub2.

Topical tacrolimus for atopic dermatitis

Jade Cury Martins  1 , Ciro Martins, Valeria Aoki, Aecio F T Gois, Henrique A Ishii, Edina M K da Silva
Affiliations

Topical tacrolimus for atopic dermatitis

Jade Cury Martins et al. Cochrane Database Syst Rev. .

Abstract

Background: Atopic dermatitis (AD) (or atopic eczema) is a chronic inflammatory skin condition that affects children and adults and has an important impact on quality of life. Topical corticosteroids (TCS) are the first-line therapy for this condition; however, they can be associated with significant adverse effects when used chronically. Tacrolimus ointment (in its 2 manufactured strengths of 0.1% and 0.03%) might be an alternative treatment. Tacrolimus, together with pimecrolimus, are drugs called topical calcineurin inhibitors (TCIs).

Objectives: To assess the efficacy and safety of topical tacrolimus for moderate and severe atopic dermatitis compared with other active treatments.

Search methods: We searched the following databases up to 3 June 2015: the Cochrane Skin Group Specialised Register, CENTRAL in the Cochrane Library (Issue 5, 2015), MEDLINE (from 1946), EMBASE (from 1974), LILACS (from 1982), and the Global Resource of Eczema Trials (GREAT database). We searched six trials registers and checked the bibliographies of included studies for further references to relevant trials. We contacted specialists in the field for unpublished data.A separate search for adverse effects of topical tacrolimus was undertaken in MEDLINE and EMBASE on 30 July 2013. We also scrutinised the U.S. Food and Drug Administration (FDA) websites for adverse effects information.

Selection criteria: All randomised controlled trials (RCTs) of participants with moderate to severe atopic dermatitis (both children and adults) using topical tacrolimus at any dose, course duration, and follow-up time compared with other active treatments.

Data collection and analysis: Two authors independently screened and examined the full text of selected studies for compliance with eligibility criteria, risk of bias, and data extraction. Our three prespecified primary outcomes were physician's assessment, participant's self-assessment of improvement, and adverse effects. Our secondary outcomes included assessment of improvement of the disease by validated or objective measures, such as SCORAD (SCORing Atopic Dermatitis), the EASI (Eczema Area and Severity Index), and BSA (Body Surface Area) scores.

Main results: We included 20 studies, with 5885 participants. The variability of drug doses, outcomes, and follow-up periods made it difficult to carry out meta-analyses.A single trial showed that tacrolimus 0.1% was better than low-potency TCS by the physician's assessment (risk ratio (RR) 3.09, 95% confidence interval (CI) 2.14 to 4.45, 1 study, n = 371, moderate-quality evidence). It was also marginally better than low-potency TCS on face and neck areas and moderate-potency TCS on the trunk and extremities by the physician's assessment (RR 1.32, 95% CI 1.17 to 1.49, 1 study, n = 972, moderate level of evidence) and for some of the secondary outcomes. Compared with pimecrolimus 1%, people treated with tacrolimus were almost twice as likely to improve by the physician's assessment (RR 1.80, 95% CI 1.34 to 2.42, 2 studies, n = 506, moderate quality of evidence). Compared with the lower concentration of 0.03%, the tacrolimus 0.1% formulation reduced the risk of not having an improvement by 18% as evaluated by the physician's assessment (RR 0.82, 95% CI 0.72 to 0.92, 6 studies, n = 1640, high-quality evidence). Tacrolimus 0.1% compared with moderate-to-potent TCS showed no difference by the physician's assessment, and 2 secondary outcomes (1 study, 377 participants) and a marginal benefit favouring tacrolimus 0.1% was found by the participant's assessment (RR 1.21, 95% CI 1.13 to 1.29, 1 study, n = 974, low quality of evidence) and SCORAD.Based on data from 2 trials, tacrolimus 0.03% was superior to mild TCS for the physician's assessment (RR 2.58, 95% CI 1.96 to 3.38, 2 studies, n = 790, moderate-quality evidence) and the participant's self-assessment (RR 1.64, 95% CI 1.41 to 1.90, 1 study, n = 416, moderate quality of evidence). One trial showed moderate benefit of tacrolimus 0.03% compared with pimecrolimus 1% on the physician's assessment (RR 1.42, 95% CI 1.02 to 1.98, 1 study, n = 139, low-quality evidence), but the effects were equivocal when evaluating BSA. In the comparison of tacrolimus 0.03% with moderate-to-potent corticosteroids, no difference was found in most of the outcomes measured (including physician's and participant's assessment and also for the secondary outcomes), but in two studies, a marginal benefit favouring the corticosteroid group was found for the EASI and BSA scores.Burning was more frequent in those using calcineurin inhibitors than those using corticosteroid tacrolimus 0.03% (RR 2.48, 95% CI 1.96 to 3.14, 5 studies, 1883 participants, high-quality evidence), but no difference was found for skin infections. Symptoms observed were mild and transient. The comparison between the two calcineurin inhibitors (pimecrolimus and tacrolimus) showed the same overall incidence of adverse events, but with a small difference in the frequency of local effects.Serious adverse events were rare; occurred in both the tacrolimus and corticosteroid groups; and in most cases, were considered to be unrelated to the treatment. No cases of lymphoma were noted in the included studies nor in the non-comparative studies. Cases were only noted in spontaneous reports, cohorts, and case-control studies. Systemic absorption was rarely detectable, only in low levels, and this decreased with time. Exception is made for diseases with severe barrier defects, such as Netherton's syndrome, lamellar ichthyosis, and a few others, with case reports of a higher absorption. We evaluated clinical trials; case reports; and in vivo, in vitro, and animal studies; and didn't find any evidence that topical tacrolimus could cause skin atrophy.

Authors' conclusions: Tacrolimus 0.1% was better than low-potency corticosteroids, pimecrolimus 1%, and tacrolimus 0.03%. Results were equivocal when comparing both dose formulations to moderate-to-potent corticosteroids. Tacrolimus 0.03% was superior to mild corticosteroids and pimecrolimus. Both tacrolimus formulations seemed to be safe, and no evidence was found to support the possible increased risk of malignancies or skin atrophy with their use. The reliability and strength of the evidence was limited by the lack of data; thus, findings of this review should be interpreted with caution. We did not evaluate costs.

PubMed Disclaimer

Conflict of interest statement

Jade Cury Martins: nothing to declare. Ciro Martins: nothing to declare. Valeria Aoki: nothing to declare. Aecio FT Gois: nothing to declare. Henrique Akira Ishii: nothing to declare. Edina MK da Silva: nothing to declare.

Figures

1
1
Study flow diagram
2
2
'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies
3
3
'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study
4
4
Forest plot of comparison: 2 Tacrolimus 0.1% versus pimecrolimus 1%, outcome: 2.1 Physician's assessment of global response of improvement, clear or excellent
5
5
Forest plot of comparison: 3 Tacrolimus 0.03% versus corticosteroids, outcome: 3.1 Physician's assessment of global response of improvement, clear or excellent
6
6
Forest plot of comparison: 4 Tacrolimus 0.03% versus tacrolimus 0.1%, outcome: 4.1 Physician's assessment of global response of improvement, clear or excellent
1.1
1.1. Analysis
Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 1 Physician's assessment of global response of improvement, clear or excellent.
1.2
1.2. Analysis
Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 2 Adverse effects: burning.
1.3
1.3. Analysis
Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 3 Adverse effects: pruritus.
1.4
1.4. Analysis
Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 4 Adverse effects: skin infection.
1.5
1.5. Analysis
Comparison 1 Tacrolimus 0.1% versus steroids, Outcome 5 SCORAD: 3 weeks.
2.1
2.1. Analysis
Comparison 2 Tacrolimus 0.1% versus pimecrolimus 1%, Outcome 1 Physician's assessment of global response of improvement, clear or excellent.
2.2
2.2. Analysis
Comparison 2 Tacrolimus 0.1% versus pimecrolimus 1%, Outcome 2 Adverse effects ‐ 6 weeks.
3.1
3.1. Analysis
Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 1 Physician's assessment of global response of improvement, clear or excellent.
3.2
3.2. Analysis
Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 2 Participants's assessment of global response of improvement better or much better.
3.3
3.3. Analysis
Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 3 Adverse effects: burning.
3.4
3.4. Analysis
Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 4 Adverse effects: pruritus.
3.5
3.5. Analysis
Comparison 3 Tacrolimus 0.03% versus steroids, Outcome 5 Adverse effects: skin infection.
4.1
4.1. Analysis
Comparison 4 Tacrolimus 0.03% versus tacrolimus 0.1%, Outcome 1 Physician's assessment of global response of improvement, clear or excellent.
4.2
4.2. Analysis
Comparison 4 Tacrolimus 0.03% versus tacrolimus 0.1%, Outcome 2 Adverse effects.
5.1
5.1. Analysis
Comparison 5 Tacrolimus 0.03% versus pimecrolimus 1%, Outcome 1 Physician's assessment of global response of improvement.
5.2
5.2. Analysis
Comparison 5 Tacrolimus 0.03% versus pimecrolimus 1%, Outcome 2 Adverse effects.
6.1
6.1. Analysis
Comparison 6 Tacrolimus 0.1% versus ciclosporin, Outcome 1 Adverse effects.
6.2
6.2. Analysis
Comparison 6 Tacrolimus 0.1% versus ciclosporin, Outcome 2 SCORAD.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD009864

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Antiga 2010 {published data only}
    1. Antiga E, Volpi W, Torchia D, Fabbri P, Caproni M. Effects of tacrolimus ointment on Toll‐like receptors in atopic dermatitis. Clinical & Experimental Dermatology 2011;36(3):235‐41. [MEDLINE: ] - PubMed
Bieber 2007 {published data only}
    1. Bieber T, Vick K, Folster‐Holst R, Belloni‐Fortina A, Stadtler G, Worm M, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007;62(2):184‐9. [MEDLINE: ] - PubMed
Boguniewicz 1998 {published data only}
    1. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle‐controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Journal of Allergy & Clinical Immunology 1998;102(4 Pt 1):637‐44. [MEDLINE: ] - PubMed
Caproni 2007 {published data only}
    1. Caproni M, Torchia D, Antiga E, Terranova M, Volpi W, Bianco E, et al. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study. British Journal of Dermatology 2007;156(2):312‐9. [MEDLINE: ] - PubMed
Doss 2010 {published data only}
    1. Doss N, Kamoun MR, Dubertret L, Cambazard F, Remitz A, Lahfa M, et al. Efficacy of tacrolimus 0.03% ointment as second‐line treatment for children with moderate‐to‐severe atopic dermatitis: evidence from a randomized, double‐blind non‐inferiority trial vs. fluticasone 0.005% ointment. Pediatric Allergy & Immunology 2010;21(2 Pt 1):321‐9. [MEDLINE: ] - PubMed
Dou 2006 {published data only}
    1. Dou X, Liu L‐L, Xie Z‐Q, Chen L‐J, Li L, Feng S‐Y, et al. The impact of tacrolimus ointment on health‐related quality of life of Chinese adult and pediatric patients with atopic dermatitis (Chinese). Journal of Clinical Dermatology 2006;35(1):50‐2.
Draelos 2005 {published data only}
    1. Draelos Z, Nayak A, Pariser D, Shupack JL, Chon K, Abrams B, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‐blind comparison. Journal of the American Academy of Dermatology 2005;53(4):602‐9. [MEDLINE: ] - PubMed
Fleischer 2007 {published data only}
    1. Fleischer AB Jr, Abramovits W, Breneman D, Jaracz E, US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. Journal of Dermatological Treatment 2007;18(3):151‐7. [MEDLINE: ] - PubMed
Hanifin 2001 {published data only}
    1. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. Journal of the American Academy of Dermatology 2001;44(Suppl 1):S28‐38. [EMBASE: 2001020450] - PubMed
    1. Soter NA, Fleischer Jr AB, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. Journal of the American Academy of Dermatology 2001;44(1 Suppl):S39‐46. [DOI: 10.1067/mjd.2001.109817; EMBASE: 2001020451] - DOI - PubMed
Hung 2007 {published data only}
    1. Hung SH, Lin YT, Chu CY, Lee CC, Liang TC, Yang YH, et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma, & Immunology 007;98(1):51‐6. [MEDLINE: ] - PubMed
Kempers 2004 {published data only}
    1. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, et al. A randomized investigator‐blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. Journal of the American Academy of Dermatology 2004;51(4):515‐25. [MEDLINE: ] - PubMed
Otsuki 2003 {published data only}
    1. Otsuki, M, Kawashima, M, Shibata, Y, Nakagawa, H, Harada, S. Efficacy and Safety of FK506 (Tacrolimus) Ointment in Children with Atopic Dermatitis‐Phase III Double‐blinded Comparison with Vehicle Ointment. Journal of Clinical Therapeutics & Medicines (Rinsho Iyaku) 2003;19:569‐95.
Pacor 2004 {published data only}
    1. Pacor ML, Lorenzo G, Martinelli N, Mansueto P, Rini GB, Corrocher R. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical & Experimental Allergy 2004;34(4):639‐45. [MEDLINE: ] - PubMed
Paller 2001 {published data only}
    1. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12‐week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology 2001;44(1 Suppl):S47‐57. [MEDLINE: ] - PubMed
Paller 2005 {published data only}
    1. Abramovits W, Fleischer AB Jr, Jaracz E, Breneman D. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. Journal of Drugs in Dermatology 2008;7(12):1153‐8. [MEDLINE: ] - PubMed
    1. Paller AS, Lebwohl M, Fleischer AB Jr, Antaya R, Langley RG, Kirsner RS, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. Journal of the American Academy of Dermatology 2005;52(5):810‐22. [MEDLINE: ] - PubMed
Reitamo 2002a {published data only}
    1. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. Journal of Allergy & Clinical Immunology 2002;109(3):547‐55. [MEDLINE: ] - PubMed
Reitamo 2002b {published data only}
    1. Reitamo S, Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. Journal of Allergy & Clinical Immunology 2002;109(3):539‐46. [MEDLINE: ] - PubMed
Reitamo 2004 {published data only}
    1. Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel‐Koomen C, Valk P, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double‐blind controlled trial. British Journal of Dermatology 2004;150(3):554‐62. [MEDLINE: ] - PubMed
Reitamo 2005 {published data only}
    1. Mandelin J, Remitz A, Virtanen H, Reitamo S. One‐year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double‐blind, comparative trial. Acta Dermato‐Venereologica 2010;90(2):170‐4. [DOI: 10.2340/00015555-0803; MEDLINE: ] - DOI - PubMed
    1. Poole CD, Chambers C, Allsopp R, Currie CJ. Quality of life and health‐related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. Journal of the European Academy of Dermatology & Venereology 2010;24(6):674‐8. [DOI: 10.1111/j.1468-3083.2009.03485.x; MEDLINE: ] - DOI - PubMed
    1. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster‐Holst R, et al. A multicentre, randomized, double‐blind, controlled study of long‐term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology 2005;152(6):1282‐9. [MEDLINE: ] - PubMed
Sikder 2005 {published data only}
    1. Sikder Md AU, Al Mamun S, Khan RM, Chowdhury AH, Khan HM, Hoque MM. Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis ‐ An open randomized comparative study. Journal of Pakistan Association of Dermatologists 2005;15(4):304‐12. [EMBASE: 2006159825]

References to studies excluded from this review

Arkwright 2006 {published data only}
    1. Arkwright PD, Gillespie MC, Ewing CI, David TJ. Blinded side‐to‐side comparison of topical corticosteroid and tacrolimus ointment in children with moderate to severe atopic dermatitis. Clinical & Experimental Dermatology 2007;32(2):145‐7. [MEDLINE: ] - PubMed
Chapman 2005 {published data only}
    1. Chapman MS, Schachner LA, Breneman D, Boguniewicz M, Gold MH, Shull T, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology 2005;53(2 Suppl 2):177‐85. [MEDLINE: ] - PubMed
Dähnhardt‐Pfeiffer 2013 {published data only}
    1. Dähnhardt‐Pfeiffer S, Dähnhardt D, Buchner M, Walter K, Proksch E, Fölster‐Holst R. Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis. Journal Der Deutschen Dermatologischen Gesellschaft 2013;11(5):437‐43. [MEDLINE: ] - PubMed
del Rosso 2007 {published data only}
    1. Rosso JQ, Conte ET. An Investigator‐Blinded Evaluation of Fluocinonide 0.1% Cream in the Treatment of Atopic Dermatitis and Psoriasis Vulgaris. Cosmetic Dermatology 2007;20(9):545‐52. [EMBASE: 2007500429]
Doss 2009 {published data only}
    1. Doss N, Reitamo S, Dubertret L, Fekete GL, Kamoun MR, Lahfa M, et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double‐blind trial. British Journal of Dermatology 2009;161(2):427‐34. [MEDLINE: ] - PubMed
Gradman 2007 {published data only}
    1. Gradman J, Wolthers OD. Short‐term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus. Acta Paediatrica 2007;96(8):1233‐7. [MEDLINE: ] - PubMed
Granlund 2001 {published data only}
    1. Granlund H, Remitz A, Kyllonen H, Lauerma AI, Reitamo S. Treatment of Lichenified Atopic Eczema with Tacrolimus Ointment. Acta Dermato‐Venereologica 2001;81(4):314‐5. [MEDLINE: ] - PubMed
Hebert 2006 {published data only}
    1. Hebert AA, Koo J, Fowler J, Berman B, Rosenberg C, Levitt J. Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. Cutis 2006;78(5):357‐63. [MEDLINE: ] - PubMed
Hjelmgren 2007 {published data only}
    1. Hjelmgren J, Svensson A, Jorgensen ET, Lindemalm‐Lundstam B, Ragnarson Tennvall G. Cost‐effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health‐economic model simulation based on a patient survey and clinical trial data. British Journal of Dermatology 2007;156(5):913‐21. [MEDLINE: ] - PubMed
Ishibashi 1997 {published data only}
    1. Ishibashi Y, Nakagawa H, Eto T, Kawashima M, Higaki Y, Harada S, et al. Early Phase II Study of FK506 Ointment on Atopic Dermatitis. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines) 1997;13(2):317‐39.
Kang 2003 {published data only}
    1. Kang S, Paller A, Soter N, Satoi Y, Rico MJ, Hanifin JM. Safe treatment of head/neck AD with tacrolimus ointment. Journal of Dermatological Treatment 2003;14(2):86‐94. [MEDLINE: ] - PubMed
Kirsner 2010 {published data only}
    1. Kirsner RS, Heffernan MP, Antaya R. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta Dermato‐Venereologica 2010;90(1):58‐64. [MEDLINE: ] - PubMed
Liu 2005 {published data only}
    1. Liu LL, Dou X, Xie ZQ, Wand D, Zheng ZZ, Wei MH, et al. Efficacy and Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis in Chinese Children. Chinese Journal of Dermatology 2005;38(10):608‐11.
Neumann 2008 {published data only}
    1. Neumann E, Amtage D, Bruckner‐Tuderman L, Mockenhaupt M. A single‐center open‐label long‐term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. Journal Der Deutschen Dermatologischen Gesellschaft 2008;6(7):548‐53. [MEDLINE: ] - PubMed
Onumah 2013 {published data only}
    1. Onumah N, Kircik L. Pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis: A pilot study on patient preference. Journal of Drugs in Dermatology 2013;12(10):1145‐8. [MEDLINE: ] - PubMed
Rahman 2008 {published data only}
    1. Rahman MF, Rashid MM, Sikder AU, Akhtar N, Banu LA, Wahab MA. Efficacy of topical tacrolimus in atopic dermatitis. Journal of Pakistan Association of Dermatologists 2008;18(2):84‐92. [EMBASE: 2008404671]
Reitamo 2009 {published data only}
    1. Reitamo S, Mandelin J, Rubins A, Remitz A, Makela M, Cirule K, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. International Journal of Dermatology 2009;48(4):348‐55. [MEDLINE: ] - PubMed
Ruzicka 1997 {published data only}
    1. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, et al. A short‐term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. New England Journal of Medicine 1997;337(12):816‐21. [MEDLINE: ] - PubMed
Schachner 2005 {published data only}
    1. Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double‐blind, vehicle‐controlled study. Pediatrics 2005;116(3):e334‐42. [MEDLINE: ] - PubMed
Takeuchi 2012 {published data only}
    1. Takeuchi S, Saeki H, Tokunaga S, Sugaya M, Ohmatsu H, Tsunemi Y, et al. A randomized, open‐label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis. Annals of Dermatology 2012;24(2):144‐50. [MEDLINE: ] - PMC - PubMed
Torok 2003 {published data only}
    1. Torok HM, Maas‐Irslinger R, Slayton RM. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis 2003;72(2):161‐6. [MEDLINE: ] - PubMed
Won 2004 {published data only}
    1. Won CH, Seo PG, Park YM, Yang JM, Lee KH, Sung KJ, et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. Journal of Dermatological Treatment 2004;15(1):30‐4. [MEDLINE: ] - PubMed
Xhauflaire‐Uhoda 2007 {published data only}
    1. Xhauflaire‐Uhoda E, Thirion L, Piérard‐Franchimont C, Piérard GE. Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis. Dermatology 2007;214(4):328‐32. [MEDLINE: ] - PubMed

References to studies awaiting assessment

Drake 2001 {published data only}
    1. Drake L, Prendergast M, Maher R, Breneman D, Korman N, Satoi Y, et al. The impact of tacrolimus ointment on health‐related quality of life of adult and pediatric patients with atopic dermatitis. Journal of the American Academy of Dermatology 2001;44(1 Suppl):S65‐72. [MEDLINE: ] - PubMed

References to ongoing studies

NCT00475605 {published data only}
    1. NCT00475605. APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long‐Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT00475605 (accessed 8 October 2014).

Additional references

Akdis 2006
    1. Akdis CA, Akdis M, Bieber T, Bindslev‐Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006;61(8):969‐987. [MEDLINE: ] - PubMed
Aldea 2012
    1. Aldea A, Garcia Sanchez‐Colomer M, Fernandez Quintana E, Garcia Saiz M. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. European Journal of Clinical Pharmacology 2012;68(9):1329‐38. [MEDLINE: ] - PubMed
Allen 2001
    1. Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Archives of Dermatology 2001;137(6):747‐50. [MEDLINE: ] - PubMed
Allen 2002
    1. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Archives of Dermatology 2002;138(9):1259‐60. [MEDLINE: ] - PubMed
Antille 2004
    1. Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Archives of Dermatology 2004;140(4):457‐60. [MEDLINE: ] - PubMed
Arellano 2007
    1. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. Journal of Investigative Dermatology 2007;127(4):808‐16. [MEDLINE: ] - PubMed
Arellano 2009
    1. Arellano FM, Arana A, Wentworth CE, Fernandez‐Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. Journal of Allergy & Clinical Immunology 2009;123(5):1111‐6. [MEDLINE: ] - PubMed
Ashcroft 2005
    1. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta‐analysis of randomised controlled trials. BMJ 2005;330(7490):516. [MEDLINE: ] - PMC - PubMed
Ashcroft 2005b
    1. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta‐analysis of randomised controlled trials. BMJ 2005;330(7490):516. [MEDLINE: ] - PMC - PubMed
Ashcroft 2007
    1. Ashcroft DM, Chen L, Garside R, Stein K, Williams HC. Topical pimecrolimus for eczema. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005500.pub2] - DOI - PMC - PubMed
Asher 2010
    1. Asher MI, Stewart AW, Mallol J, Montefort S, Lai CK, Aït‐Khaled N, et al. Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One. Respiratory Research 2010;11:8. [MEDLINE: ] - PMC - PubMed
Bath‐Hextall 2008
    1. Bath‐Hextall FJ, Delamere FM, Williams HC. Dietary exclusions for established atopic eczema. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD005203.pub2] - DOI - PMC - PubMed
Bekersky 2001
    1. Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. Journal of the American Academy of Dermatology 2001;44(1 Suppl):S17‐27. [MEDLINE: ] - PubMed
Bens 2003
    1. Bens G, Boralevi F, Buzenet C, Taïeb A. Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. British Journal of Dermatology 2003;149(1):224‐226. [MEDLINE: ] - PubMed
Berger 2006
    1. Berger TG, Duvic M, Voorhees AS, VanBeek MJ, Frieden IJ, American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. Journal of the American Academy of Dermatology 2006;54(5):818‐23. [MEDLINE: ] - PubMed
Beyeler 2006
    1. Beyeler M, Schmid‐Grendelmeier P, Hafner J. Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis. Dermatology 2006;212(3):260‐261. [MEDLINE: ] - PubMed
Boguniewicz 2006
    1. Boguniewicz M, Leung DY. Atopic Dermatitis. Journal of Allergy & Clinical Immunology 2006;117(2 Suppl Mini‐Primer):S475‐S480. [MEDLINE: ] - PubMed
Bos 2010
    1. Bos JD, Brenninkmeijer EE, Schram ME, Middelkamp‐Hup MA, Spuls PI, Smitt JH. Atopic eczema or atopiform dermatitis. Experimental Dermatology 2010;19(4):325‐31. [MEDLINE: ] - PubMed
Brenninkmeijer 2009
    1. Brenninkmeijer EE, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD. The course of life of patients with childhood atopic dermatitis. Pediatric Dermatology 2009 Jan‐Feb;26(1):14‐22. [MEDLINE: ] - PubMed
Breuer 2005
    1. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology 2005;6(2):65‐77. [MEDLINE: ] - PubMed
Böhme 2001
    1. Böhme M, Svensson A, Kull I, Nordvall SL, Wahlgren CF. Clinical features of atopic dermatitis at two years of age: a prospective, population‐based case‐control study. Acta Dermato‐Venereologica 2001;81(3):193‐7. [MEDLINE: ] - PubMed
Callen 2007
    1. Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, et al. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology 2007;156(2):203‐21. [MEDLINE: ] - PubMed
Calza 2005
    1. Calza AM, Lubbe J. Tacrolimus ointment‐associated alcohol intolerance in infants receiving ethanol‐containing medication. British Journal of Dermatology 2005;152(3):569. [MEDLINE: ] - PubMed
Castelo‐Soccio 2012
    1. Castelo‐Soccio L, Marcantonio D, Shah P, Lee LW, Treat JR, Yan AC. Induced lentiginosis with use of topical calcineurin inhibitors. Archives of Dermatology 2012;148(6):766‐8. [MEDLINE: ] - PubMed
Chamlin 2004
    1. Chamlin SL, Frieden IJ, Williams ML, Chren MM. Effects of atopic dermatitis on young American children and their families. Pediatrics 2004;114(3):607‐11. [MEDLINE: ] - PubMed
Charman 2000
    1. Charman C, Williams H. Outcome Measures of Disease Severity in Atopic Eczema. Archives of Dermatology 2000;136(6):763‐9. [DOI: 10.1001/archderm.136.6.763; MEDLINE: ] - DOI - PubMed
Chen 2010
    1. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta‐analysis of randomized clinical trials. Journal of Dermatological Treatment 2010;21(3):144‐56. [MEDLINE: ] - PubMed
Cho 2004
    1. Cho M, Puma I, Nguyen D, Schut R, Glesne L. Development of Kaposi's sarcoma in an AIDS patient after treatment with topical tacrolimus. Journal of the American Academy of Dermatology 2004;50(1):149‐50. [MEDLINE: ] - PubMed
Czarnecka‐Operacz 2012
    1. Czarnecka‐Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis ‐ an update on safety issues. Journal Der Deutschen Dermatologischen Gesellschaft 2012;10(3):167‐72. [MEDLINE: ] - PubMed
Ehst 2004
    1. Ehst BD, Warshaw EM. Alcohol‐induced application site erythema after topical immunomodulator use and its inhibition by aspirin. Archives of Dermatology 2004;140(8):1014‐5. [MEDLINE: ] - PubMed
Eichenfield 2014
    1. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology 2014;70(2):338‐51. [MEDLINE: ] - PMC - PubMed
El‐Batawy 2009
    1. El‐Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta‐analysis. Journal of Dermatological Science 2009;54(2):76‐87. [MEDLINE: ] - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. [MEDLINE: ] - PubMed
Ellis 2012
    1. Ellis CN, Mancini AJ, Paller AS, Simpson EL, Eichenfield LF. Understanding and managing atopic dermatitis in adult patients. Seminars in Cutaneous Medicine & Surgery 2012;31(3 Suppl):S18‐22. [MEDLINE: ] - PubMed
Ellwood 2001
    1. Ellwood P, Asher MI, Björkstén B, Burr M, Pearce N, Robertson CF. Diet and asthma, allergic rhinoconjunctivitis and atopic eczema symptom prevalence: an ecological analysis of the International Study of Asthma and Allergies in Childhood (ISAAC) data. ISAAC Phase One Study Group. European Respiratory Journal 2001 Mar;17(3):436‐43. [MEDLINE: ] - PubMed
Finch 2010
    1. Finch J, Munhutu MN, Whitaker‐Worth DL. Atopic dermatitis and nutrition. Clinics in Dermatology 2010;28(6):605‐14. [MEDLINE: ] - PubMed
Fitzpatrick 2008
    1. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. Fitzpatrick's Dermatology in General Medicine. 7th Edition. Vol. 1, United States: The McGraw‐Hill Companies, 2008.
FK506 Ointment Study Group 2001
    1. FK506 Ointment Study Group. Long‐term study of FK506 (tacrolimus) ointment in patients with atopic dermatitis ‐ analysis at time of completion of 2‐year observation. Journal of Clinical Therapeutics and Medicines 2001;17(5):705‐726.
Fonacier 2005
    1. Fonacier L, Spergel J, Charlesworth EN, Weldon D, Beltrani V, Bernhisel‐Broadbent J, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. Journal of Allergy & Clinical Immunology 2005;115(6):1249‐53. [MEDLINE: ] - PubMed
Fujiwara 2010
    1. Fujiwara S, Okubo Y, Irisawa R, Tsuboi R. Rosaceiform dermatitis associated with topical tacrolimus treatment. Journal of the American Academy of Dermatology 2010;62(6):1050‐2. [MEDLINE: ] - PubMed
Goldman 2001
    1. Goldman D. Tacrolimus ointment for thetreatment of steroid‐induced rosacea: a preliminary report. Journal of the American Academy of Dermatology 2001;44(6):995‐8. [MEDLINE: ] - PubMed
Gontijo 2008
    1. Gontijo B, Pires MC, Cestari TF, Scala CSK, Duarte IAG, Takaoka R, et al. Evaluate of the efficacy and safety of tacrolimus ointment 0, 03% to treat atopic dermatitis in pediatric patients [Avaliacao da eficacia e seguranca do tacrolimo pomada 0, 03% no tratamento da dermatite atopica em pacientes pediatricos]. Anais Brasileiros De Dermatologia 2008;83(6):511‐9. [MEDLINE: ]
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6. [EMBASE: 2008218668] - PMC - PubMed
Hanifin 1980
    1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato‐Vereneologica 1980;92(Suppl):44‐7.
Hanifin 2001b
    1. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Experimental Dermatology 2001;10(1):11‐8. [MEDLINE: ] - PubMed
Harper 2005
    1. Harper J, Smith C, Rubins A, Green A, Jackson K, Zigure S, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. Journal of Investigative Dermatology 2005;124(4):695‐9. [MEDLINE: ] - PubMed
Harrop 2007
    1. Harrop J, Chinn S, Verlato G, Olivieri M, Norbäck D, Wjst M, et al. Eczema, atopy and allergen exposure in adults: a population‐based study. Clinical & Experimental Allergy 2007;37(4):526‐35. [MEDLINE: ] - PubMed
Hickey 2004
    1. Hickey JR, Robson A, Barker JN, Smith CH. Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. British Journal of Dermatology 2005;152(1):152‐4. [MEDLINE: ] - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org.
Hui 2009
    1. Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Annals of Pharmacotherapy 2009;43(12):1956‐63. [MEDLINE: ] - PubMed
Hultsch 2005
    1. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005;211(2):174‐87. [MEDLINE: ] - PubMed
Jenkinson 1999
    1. Jenkinson C, Stewart‐Brown S, Petersen S, Paice C. Assessment of theSF‐36 version 2 in the United Kingdom. Journal of Epidemiology & Community Health 1999;53(1):46‐50. [MEDLINE: ] - PMC - PubMed
Johansson 2004
    1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy & Clinical Immunology 2004;113(5):832‐6. [MEDLINE: ] - PubMed
Karagas 2001
    1. Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non‐melanoma skin cancers and glucocorticoid therapy. British Journal of Cancer 2001;85(5):683‐6. [MEDLINE: ] - PMC - PubMed
Knight 2005
    1. Knight AK, Boxer M, Chandler MJ. Alcohol‐induced rash caused by topical tacrolimus. Annals of Allergy, Asthma, & Immunology 2005;95(3):291‐2. [MEDLINE: ] - PubMed
Knowles 1999
    1. Knowles DM. Immunodeficiency‐associated lymphoproliferative disorders. Modern Pathology 1999;12(2):200‐17. [MEDLINE: ] - PubMed
Koo 2005
    1. Koo JY, Fleischer AB Jr, Abramovits W, Pariser DM, McCall CO, Horn TD, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. Journal of the American Academy of Dermatology 2005;53(2 Suppl 2):S195‐205. [MEDLINE: ] - PubMed
Kyllönen 2004
    1. Kyllönen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1‐year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. British Journal of Dermatology 2004;150(6):1174‐1181. [MEDLINE: ] - PubMed
Lepe 2003
    1. Lepe V, Moncada B, Castanedo‐Cazares JP, Torres‐Alvarez MB, Ortiz CA, Torres‐Rubalcava AB. A double‐blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Archives of Dermatology 2003;139(5):581‐585. [MEDLINE: ] - PubMed
Lin 2007
    1. Lin Y, Sun IW, Liu SI, Loh el‐W, Lin YC. Tacrolimus ointment‐induced relapse of schizophrenia: a case report. International Journal of Neuropsychopharmacology 2007;10(6):851‐4. [MEDLINE: ] - PubMed
Lotti 2008
    1. Lotti T, Buggiani G, Troiano M, Assad GB, Delescluse J, Giorgi V, et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatologic Therapy 2008;21(Suppl 1):S20‐6. [MEDLINE: ] - PubMed
Luger 2005
    1. Luger TA, Gollnick H. Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis) [Stellungnahme Der Deutschen Dermatologischen Gesellschaft (DDG) Zur Entscheidung Der Amerikanischen Arzneimittelbehorde (FDA) Uber Die Verwendung Von Pimecrolimus‐Creme Und Tacrolimus‐Salbe Zur Behandlung Der Atopischen Dermatitis (Neurodermitis)]. Journal Der Deutschen Dermatologischen Gesellschaft 2005;3(6):415‐6. [MEDLINE: ] - PubMed
Luger 2011
    1. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. Journal of the European Academy of Dermatology & Venereology 2011;25(3):251‐8. [MEDLINE: ] - PubMed
Macias 2011
    1. Macias ES, Pereira FA, Rietkerk W, Safai B. Superantigens in dermatology. Journal of the American Academy of Dermatology 2011;64(3):455‐72. [MEDLINE: ] - PubMed
Maddin 2005
    1. Maddin S. Pimecrolimus and tacrolimus: the US FDA public health advisory. Skin Therapy Letter 2005;10(4):1‐3. [MEDLINE: ] - PubMed
Maksimovic 2012
    1. Maksimović N, Janković S, Marinković J, Sekulović LK, Zivković Z, Spirić VT. Health‐related quality of life in patients with atopic dermatitis. Journal of Dermatology 2012;39(1):42‐7. [MEDLINE: ] - PubMed
Mandelin 2012
    1. Mandelin JM, Rubins A, Remitz A, Cirule K, Dickinson J, Ho V, et al. Long‐term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two‐year open‐label study. International Journal of Dermatology 2012;51(1):104‐10. [MEDLINE: ] - PubMed
Margolis 2007
    1. Margolis DJ, Hoffstad O, Bilker, W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214(4):289‐95. [MEDLINE: ] - PubMed
McCollum 2010
    1. McCollum AD, Paik A, Eichenfield LF. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatric Dermatology 2010;27(5):425‐36. [MEDLINE: ] - PubMed
Medline Plus® a
    1. Medline Plus®. Medical Dictionary. http://www.merriam‐webster.com/medlineplus/antibody (accessed 30 July 2013).
Medline Plus® b
    1. Medline Plus®. Medical Dictionary. http://www.merriam‐webster.com/medlineplus/prick%20test (accessed 30 July 2013).
Milingou 2004
    1. Milingou M, Antille C, Sorg O, Saurat JH, Lubbe J. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Archives of Dermatology 2004;140(12):1542‐4. [MEDLINE: ] - PubMed
Mitamura 2011
    1. Mitamura T, Doi Y, Kawabe M, Lilja H, Motomura M, Oishi Y, et al. Inhibitory potency of tacrolimus ointment on skin tumor induction in a mouse model of an initiation‐promotion skin tumor. Journal of Dermatology 2011;38(6):562‐70. [MEDLINE: ] - PubMed
Momtaz 1998
    1. Momtaz K, Fitzpatrick TB. The benefits and risks of long‐term PUVAphotochemotherapy. Dermatologic Clinics 1998;16(2):227‐34. [MEDLINE: ] - PubMed
Naylor 2005
    1. Naylor M, Elmets C, Jaracz E, Rico JM. Non‐melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. Journal of Dermatological Treatment 2005;16(3):149‐53. [MEDLINE: ] - PubMed
Odhiambo 2009
    1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy & Clinical Immunology 2009;124(6):1251‐8. [MEDLINE: ] - PubMed
Ormerod 2005
    1. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?. British Journal of Dermatology 2005;153(4):701‐5. [MEDLINE: ] - PubMed
Patel 2003
    1. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Archives of Dermatology 2003;139(9):1184‐6. [MEDLINE: ] - PubMed
Patel 2007
    1. Patel TS, Greer SC, Skinner RB Jr. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. American Journal of Clinical Dermatology 2007;8(4):189‐94. [MEDLINE: ] - PubMed
Pitarch 2006
    1. Pitarch G, Torrijos A, Mahiques L, Sánchez‐Carazo JL, Fortea JM. Systemic absorption of topical tacrolimus in Pyoderma gangrenosum. Acta Dermato‐Venereologica 2006;86(1):64‐65. [MEDLINE: ] - PubMed
Rajka 1989
    1. Rajka G, Langeland T. Grading of the severity of atopic dermatits. Acta Dermato‐Venereologica. Supplementum 1989;144:13‐4. [MEDLINE: ] - PubMed
Rehal 2011
    1. Rehal B, Armstrong AW. Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality‐of‐Life Instruments 1985–2010. PLoS ONE 2011;6(4):e17520. [DOI: 10.1371/journal.pone.0017520; MEDLINE: ] - DOI - PMC - PubMed
Reitamo 1998
    1. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single‐center randomized trial. Journal of Investigative Dermatology 1998;111(3):396‐8. [MEDLINE: ] - PubMed
Reitamo 2000
    1. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis.The European Tacrolimus OintmentStudy Group. Archives of Dermatology 2000;136(8):999‐1006. [MEDLINE: ] - PubMed
Reitamo 2006
    1. Reitamo S, Rubins A, Ho V, et al. Pharmacokinetics of topical tacrolimus in paediatric patients aged 3 to 24 months. 15th Congress of the European Academy of Dermatology andVenereology, Rhodes, Greece. 2006.
Reitamo 2007
    1. Reitamo S, Ortonne JP, Sand C, Bos J, Cambazard F, Bieber T, et al. Long‐term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two‐year, multicentre, non‐comparative study. Acta Dermato‐Venereologica 2007;87(5):406‐12. [EMBASE: 17721647] - PubMed
Reitamo 2008
    1. Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, et al. A 4‐year follow‐up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. British Journal of Dermatology 2008;159(4):942‐51. [MEDLINE: ] - PubMed
Remitz 2007
    1. Remitz A, Harper J, Rustin M, Goldschmidt WF, Palatsi R, Valk PG, et al. Long‐term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Dermato‐Venereologica 2007;87(1):54‐61. [MEDLINE: ] - PubMed
Ring 2005
    1. Ring J, Barker J, Behrendt H, Braathen L, Darsow U, Dubertret L, et al. Review of the potential photo‐cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. Journal of the European Academy of Dermatology & Venereology 2005;19(6):663‐71. [MEDLINE: ] - PubMed
Roekevisch 2014
    1. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate‐to‐severe atopic dermatitis: A systematic review. Journal of Allergy & Clinical Immunology 2014;133(2):429‐438. [MEDLINE: ] - PubMed
Rustin 2007
    1. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. British Journal of Dermatology 2007;157(5):861‐73. [MEDLINE: ] - PubMed
Saif 2007
    1. Saif GB, Al‐Khenaizan S. Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. International Journal of Dermatology 2007;46(3):290‐294. [MEDLINE: ] - PubMed
Saple 2003
    1. Saple DG, Torsekar RG, Pawanarkar V, Wali V, Ravichandran G, Dhanalakshmi UR, et al. Evaluation of the efficacy, safety and tolerability of Tacrolimus ointment in Indian patients of moderate to severe atopic dermatitis: a multicentric, open label, phase III study. Indian Journal of Dermatology, Venereology & Leprology 2003;69(6):396‐400. [MEDLINE: ] - PubMed
Schmitt 2011
    1. Schmitt J, Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta‐analysis of randomized controlled trials. British Journal of Dermatology 2011;164(2):415‐28. [MEDLINE: ] - PubMed
Schmutz 2006
    1. Schmutz JL, Barbaud A, Trechot P. Kaposi's sarcoma in an AIDS patient after application of tacrolimus (Protopic) [Maladie de Kaposi chez un sujet sideen apres application de tacrolimus (Protopic)]. Annales de Dermatologie et de Venereologie 2006;133(3):303. [MEDLINE: ] - PubMed
Schneeweiss 2009
    1. Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez‐Vidaurre C, et al. Topical treatments with pimecrolimus, tacrolimus and medium‐ to high‐potency corticosteroids, and risk of lymphoma. Dermatology 2009;219(1):7‐21. [MEDLINE: ] - PubMed
Schwarz 2008
    1. Schwarz T, Kreiselmaier I, Bieber T, Thaci D, Simon JC, Meurer M, et al. A randomized, double‐blind, vehicle‐controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. Journal of the American Academy of Dermatology 2008;59(1):34‐40. [MEDLINE: ] - PubMed
Segal 2013
    1. Segal AO, Ellis AK, Kim HL. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy, Asthma, & Clinical Immunology : Official Journal of the Canadian Society of Allergy & Clinical Immunology 2013;9(1):24. [MEDLINE: ] - PMC - PubMed
Shaw 2004
    1. Shaw DW, Eichenfield LF, Shainhouse T, Maibach HI. Allergic contact dermatitis from tacrolimus. Journal of the American Academy of Dermatology 2004;50(6):962‐5. [MEDLINE: ] - PubMed
Siegfried 2013
    1. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. American Journal of Clinical Dermatology 2013;14(3):163‐78. [MEDLINE: ] - PMC - PubMed
Simon 2014
    1. Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy 2014;69(1):46‐55. [MEDLINE: ] - PubMed
Skowron 2005
    1. Skowron F, Dalle S, Marcilly MC, Balme B, Thomas L. Important systemic absorption of topical tacrolimus during treatment of severe pemphigus vulgaris. Annales de Dermatologie et de Venereologie 2005;132(3):263‐5. [MEDLINE: ] - PubMed
Soderberg 2004
    1. Soderberg KC, Hagmar L, Schwartzbaums J, Feychting M. Allergic conditions and the risk of hematological malignancies in adults: a cohort study. BMC Public Health 2004;4:51. [MEDLINE: ] - PMC - PubMed
Sorensen 2004
    1. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non‐hodgkin lymphoma among users of systemic glucocorticoids: a population‐based cohort study. Journal of the National Cancer Institute 2004;96(9):709‐11. [MEDLINE: ] - PubMed
Stern 2001
    1. Stern RS, PUVA Follow up Study. The risk of melanoma in association with long‐term exposure to PUVA. Journal of the American Academy of Dermatology 2001;44(5):755‐61. [MEDLINE: ] - PubMed
Stiehm 2005
    1. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ. Pneumococcal seroconversion after vaccination in children with atopic dermatitis treated with tacrolimus ointment. Journal of the American Academy of Dermatology 2005;53(2 Suppl 2):S206‐13. [MEDLINE: ] - PubMed
Strachan 1989
    1. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299(6710):1259‐60. [MEDLINE: ] - PMC - PubMed
Svensson 2011
    1. Svensson A, Chambers C, Ganemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Current Medical Research & Opinion 2011;27(7):1395‐406. [MEDLINE: ] - PubMed
Tennis 2011
    1. Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. British Journal of Dermatology 2011;165(3):465‐73. [MEDLINE: ] - PubMed
Teraki 2012
    1. Teraki Y, Hitomi K, Sato Y, Izaki S. Tacrolimus‐induced rosacea‐like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application. Dermatology 2012;224(4):309‐14. [MEDLINE: ] - PubMed
Tran 2005
    1. Tran C, Lubbe J, Sorg O, Doelker L, Carraux P, Antille C, et al. Topical calcineurin inhibitors decrease the production of UVB‐induced thymine dimers from hairless mouse epidermis. Dermatology 2005;211(4):341‐7. [MEDLINE: ] - PubMed
US Food and Drug Administration
    1. US Food, Drug Administration (FDA). Pediatric Advisory Committee February 15th 2005. Briefing Information. Labeling Information and NDAs. www.fda.gov/ohrms/dockets/ac/05/briefing/2005‐4089b2.htm (accessed 5 December 2013).
Weischer 2007
    1. Weischer M, Rocken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion?. Experimental Dermatology 2007;16(5):385‐93. [MEDLINE: ] - PubMed
Williams 1999
    1. Williams H, Robertson C, Stewart A, Aït‐Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. Journal of Allergy & Clinical Immunology 1999;103(1 Pt 1):125‐38. [MEDLINE: ] - PubMed
Wong 2003
    1. Wong WR, Tsai HJ, Hong HS. Efficacy and safety of topically applied tacrolimus ointment in patients with moderate to severe atopic dermatitis. Chang Gung Medical Journal 2003;26(7):485‐95. [MEDLINE: ] - PubMed
Yan 2008
    1. Yan J, Chen SL, Wang XL, Zhou W, Wang FS. Meta‐analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatric Dermatology 2008;25(1):117‐20. [MEDLINE: ] - PubMed
Yin 2012
    1. Yin ZQ, Zhang WM, Song GX, Luo D. Meta‐analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis. Journal of Dermatology 2012;39(6):520‐6. [MEDLINE: ] - PubMed
Zattra 2010
    1. Zattra E, Albertin C, Belloni Fortina A. Labial melanotic macule after application of topical tacrolimus: two case reports. Acta Dermato‐Venereologica 2010;90(5):527. [MEDLINE: ] - PubMed
Zonneveld 1996
    1. Zonneveld IM, Rie MA, Beljaards RC, Rhee HJ, Wuite J, Zeegelaar J, et al. The long‐term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. British Journal of Dermatology 1996;135(Suppl 48):15‐20. [MEDLINE: ] - PubMed

References to other published versions of this review

Cury Martins 2012
    1. Cury Martins J, Martins C, Aoki V, Leonardi‐Bee J, Gois AFT, Ishii HA, et al. Topical tacrolimus for atopic dermatitis. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009864] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources